Locoregional Extension Patterns of Nasopharyngeal Carcinoma Detected by FDG PET/MR

Caineng Cao¹,², Yuanfan Xu³, Shuang Huang¹,², Feng Jiang¹,², Ting Jin¹,², Qifeng Jin¹,², Yonghong Hua¹,², Qiaoying Hu¹,² and Xiaozhong Chen¹,²*

¹ Department of Radiation Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Cancer Research and Basic Medicine (ICBM), Chinese Academy of Sciences, Zhejiang Provincial Key Laboratory of Radiation Oncology, Hangzhou, China, ² Key Laboratory of Head and Neck Cancer Translational Research of Zhejiang Province, Hangzhou, China, ³ Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou, China

Purpose: We sought to define the locoregional extension patterns of nasopharyngeal carcinomas (NPCs) by positron emission tomography (PET)/magnetic resonance imaging (MRI) and to improve clinical target volume (CTV) delineation.

Methods: Between May 2017 and March 2021, 331 consecutive patients with nonmetastatic NPCs who underwent pretreatment, simultaneous whole-body PET/MRI for staging were included in this study.

Results: The high-risk regions included the base of the sphenoid bone, the prestyloid compartment, prevertebral muscle, foramen lacerum, medial pterygoid plate, sphenoidal sinus, clivus, petrous apex, and foramen ovale. When the high-risk regions were invaded, the incidence rates of tumor invasion into the medium-risk regions increased. In contrast, when the high-risk regions were not involved, the incidence rates of tumor invasion into the medium-risk regions were mostly less than 10%, excluding the post-styloid compartment and oropharynx. According to the updated consensus guidelines of the neck node levels for head and neck tumors from 2013, level IIa (77.3%, 256/331), level IIb (75.8%, 251/331), and level VIIa (71.3%, 236/331) were the most frequently involved levels, followed by levels III (42.6%), Va (13.9%), IVa (8.8%), IVb (3.6%), Ib (3.6%), Vb (2.4%), VIIb (2.4%), VIII (1.8%), Vc (0.9%), and Xa (0.3%). Skip lymph node metastasis occurred in only 1.9% of patients.

Conclusions: For NPCs, primary disease and regional lymph node spread follow an orderly pattern, and a skip pattern of lymph node metastasis was unusual. Involved level radiotherapy might be feasible for cervical lymph node levels below the caudal border of cricoid cartilage and level VIIb.

Keywords: nasopharyngeal carcinoma, simultaneous PET/MRI, clinical target volume, local extension, lymph node spread
INTRODUCTION

Radiotherapy is the primary treatment modality for nonmetastatic nasopharyngeal carcinomas (NPCs) (1). Target delineation of NPCs is often challenging for the proximity of the tumors to critical organs at risk such as the brain stem and spinal cord. Based on the best available investigation methods, accurate delineation of the Gross Tumor Volume (GTV) is the first step. The next step is to delineate the clinical target volume (CTV) covering the subclinical microscopic malignant lesions. However, there are many controversies on details of contouring in NPCs (2).

In the National Comprehensive Cancer Network (NCCN) guidelines, magnetic resonance imaging (MRI) with a contrast of skull base to clavicle is recommended for defining the locoregional extension of NPC, and 18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) is merely recommended for nodal and distant metastases in patients with multistation or lower neck nodal involvement or high-grade tumor histology (3). The diagnostic criteria of lymph node involvement included lymph nodes with overt FDG uptake in the international guideline for target volume delineation of NPC (4). A prospective study indicated that PET/MRI was more accurate than the combination of head and neck MRI and PET/CT in the staging of newly diagnosed NPCs (5). With the development of PET/MRI, the target volume delineation of NPCs should be reevaluated.

In our previous studies, PET/MRI for dose painting and staging was evaluated in NPC (6, 7). The aim of the present study was to define the locoregional extension patterns of NPC by PET/MRI and to improve CTV delineation.

MATERIALS AND METHODS

Patients

Between May 2017 and March 2021, 331 consecutive patients with biopsy-proven, newly diagnosed, nonmetastatic NPCs were included in this study. The pretreatment evaluation included a complete history and physical examination, fiber-optic nasopharyngoscopy, MRI of the nasopharynx and neck, and whole-body 18F-FDG PET/MR. Medical records and imaging studies were analyzed retrospectively, and all patients were staged according to the 8th edition of the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) staging system (8, 9). Patient clinicopathologic characteristics are listed in Table 1.

Whole-Body 18F-FDG PET/MR

PET/MRI was performed on a SIGNA PET/MR (GE Healthcare) by a 3-T magnetic field strength, total imaging matrix coil technology, and a fully functional PET system. The scan range covered the entire body. The details of PET/MRI were described previously (6).

Image Interpretation and Diagnostic Criteria

Interpretation of the PET/MRI fused images, plus their individual MRI and PET components, was evaluated independently by two nuclear medicine physicians who also had qualification certificates in radiology. Any discrepancy was resolved by consensus. In addition, there is a multidisciplinary team of NPC to confirm the extent of diseases and the treatment in our center (10).

Nasal cavity invasion was defined as a primary tumor invading beyond the posterior line of the pterygopalatine fossa. Oropharynx invasion was defined as a primary tumor invading below Cl/C2. Hypopharynx invasion was defined as a primary tumor invading below or the free edge of the epiglottis or the lower margin of C3. The parapharyngeal space included the prestyloid and poststyloid compartments. Parapharyngeal space invasion was defined as primary tumor invading posterolaterally beyond the pharyngobasilar fascia. Infratemporal fossa invasion was defined as a primary tumor invading into the sinus cavity with bone destruction of the wall of the sinus (10). Cavernous sinus invasion was defined as a change in contour or enlargement of the sinus (12). The primary tumor invading across the midline of the nasopharynx was classified as bilateral NPC excluding the midline anatomic sites, such as the clivus and base of the sphenoid bone. Based on the incidence rates of primary tumor involvement, the regions surrounding the nasopharynx were divided into high-risk (>5%), medium-risk (5%–35%), and low-risk (<5%) regions (11).

| TABLE 1 | Patient characteristics. |
|-----------------|--------------------------|
| **Characteristic** | **No. (%)** |
| Sex             |                           |
| Male            | 254 (76.7)                |
| Female          | 77 (23.3)                 |
| Age (years)     |                           |
| Median          | 51                       |
| Range           | 13–81                     |
| Pathology classification |                     |
| Non-keratinizing| 331 (100.0)               |
| T classification |                           |
| T1              | 22 (6.6)                  |
| T2              | 25 (7.8)                  |
| T3              | 189 (57.1)                |
| T4              | 95 (28.7)                 |
| N classification |                           |
| N0              | 20 (6.0)                  |
| N1              | 81 (24.5)                 |
| N2              | 169 (51.1)                |
| N3              | 61 (18.4)                 |
| Overall stage   |                           |
| I               | 3 (0.9)                   |
| II              | 7 (2.1)                   |
| III             | 179 (54.1)                |
| IVa             | 142 (42.9)                |

Data in parentheses are percentages.
The diagnostic criteria of regional lymph node metastases included (a) lateral retropharyngeal nodes with minimal axial diameter in the largest plane > 5 mm (any node seen in the median retropharyngeal group) or cervical lymph nodes with minimal axial diameter in the largest plane > 10 mm (11 mm for subdigastric lymph nodes); (b) three or more contiguous and confluent lymph nodes, each with the shortest diameter of 8–10 mm; and (c) lymph nodes of any size with extracapsular spread, central necrosis, or overt FDG uptake (4, 7). The assignment of neck node levels was made with reference to the 2013 updated consensus guidelines of the neck node levels for head and neck tumors (13).

Statistical Analysis
The Statistical Package for Social Sciences, version 17.0 (SPSS Inc., Chicago, IL), software was used for statistical analysis. The Chi-squared and Fisher’s exact tests were used to compare the differences between categorical variables, and a p < 0.05 was considered to be statistically significant.

RESULTS

The Risk of Tumor Invasion Into Various Anatomic Sites
The incidence rates of tumor invasion into anatomic sites for NPCs are shown in Table 2. The high-risk regions included the basis of the sphenoid bone, prestyloid compartment, prevertebral muscle, foramen lacerum, medial pterygoid plate, sphenoidal sinus, clivus, petrous apex, and foramen ovale. Excluding the nasal cavity and oropharynx, the high-risk regions were adjacent to the nasopharynx. The medium-risk regions included meninges, pterygopalatine fossa, poststyloid compartment, cavernous sinus, medial pterygoid muscle, oropharynx, hypoglossal canal, foramen rotundum, lateral pterygoid plate, jugular foramen, nasal cavity, parotid gland, and lateral pterygoid muscle.

When the high-risk regions were invaded, the incidence rates of tumor invasion into the medium-risk regions increased. In the case of the tumor invading the foramen ovale, 64.8% of patients developed meninges involvement. In contrast, when the high-risk regions were not involved, the incidence rates of tumor invasion into the medium-risk regions were mostly less than 10% excluding the poststyloid compartment and oropharynx (Table 3).

Tumor Invasion Into Bilateral Anatomical Sites
Three hundred and nineteen patients (319/331, 96.4%) had bilateral tumor invasion into the mucous membrane of the nasopharynx. The details of concurrent bilateral tumor invasion into anatomic sites for NPC are shown in Table 4. Of note, the incidence rates of concurrent bilateral tumor invasion were mostly less than 10%, excluding the prevertebral muscle (16.3%).

Skull-Base Invasion
The cumulative rates of tumor invasion into the anatomic sites of the skull are shown in Table 5. The base of sphenoid bone had the highest involvement rate (81.9%), followed by the foramen lacerum (53.2%) and medial pterygoid plate (48.3%). The incidence rates of tumor invasion into the bilateral anatomic sites such as foramen lacerum, petrous apex, medial pterygoid plate, and foramen ovale were less than 10%. No significant difference was observed in terms of cumulative incidence rates between right and left anatomic sites of skull-base invasion.

Pattern of Regional Lymph Node Metastasis
In this cohort of patients, the rate of lymph node metastasis was 94.0% (311/331), and bilateral lymph node metastasis was observed in 74.9% (248/331) of patients. With reference to 2013 updated consensus guidelines of the neck node levels for head and neck tumors, level IIa (77.3%, 256/331), level IIb (75.8%, 251/331), and level VIIa (71.3%, 236/331) were the most frequently involved levels, followed by levels III (42.6%, 141/331), Va (13.9%, 46/331), IVa (8.8%, 29/331), IVb (3.6%, 12/331), Ia (3.6%, 12/331), Vb (2.4%, 8/331), VIIb (2.4%, 8/331), VIII (1.8%, 6/331), Vc (0.9%, 3/331), and Xa (0.3%, 1/331).
| Medium-risk regions | Tumor invasion | \( p \) |
|---------------------|---------------|------|
| Basis of sphenoid bone | Invasion (n = 271) | Non-invasion (n = 60) |
| Meninges | 91 (33.6%) | 0 (0.0%) | <0.001 |
| Pterygopalatine fossa | 79 (29.2%) | 1 (1.7%) | <0.001 |
| Poststyloid compartment | 73 (26.9%) | 7 (11.7%) | 0.012 |
| Cavernous sinus | 75 (27.7%) | 0 (0.0%) | <0.001 |
| Medial pterygoid muscle | 66 (24.4%) | 3 (5.0%) | <0.001 |
| Oropharynx | 51 (18.8%) | 7 (11.7%) | 0.187 |
| Hypoglossal canal | 53 (19.6%) | 1 (1.7%) | <0.001 |
| Foramen rotundum | 52 (19.2%) | 0 (0.0%) | <0.001 |
| Lateral pterygoid plate | 47 (17.3%) | 0 (0.0%) | <0.001 |
| Jugular foramen | 36 (13.3%) | 1 (1.7%) | 0.006 |
| Nasal cavity | 25 (9.2%) | 0 (0.0%) | 0.012 |
| Parotid gland | 20 (7.4%) | 1 (1.7%) | 0.142 |
| Lateral pterygoid muscle | 19 (7.0%) | 0 (0.0%) | 0.031 |

| Prestyloid compartment | Invasion (n = 234) | Non-invasion (n = 97) |
|------------------------|-------------------|----------------------|
| Meninges | 83 (35.5%) | 8 (8.2%) | <0.001 |
| Pterygopalatine fossa | 74 (31.6%) | 6 (6.2%) | <0.001 |
| Poststyloid compartment | 80 (34.2%) | 0 (0.0%) | <0.001 |
| Cavernous sinus | 71 (30.3%) | 4 (4.1%) | <0.001 |
| Medial pterygoid muscle | 69 (29.5%) | 0 (0.0%) | <0.001 |
| Oropharynx | 58 (24.8%) | 0 (0.0%) | <0.001 |
| Hypoglossal canal | 51 (21.8%) | 3 (3.1%) | <0.001 |
| Foramen rotundum | 49 (20.9%) | 3 (3.1%) | <0.001 |
| Lateral pterygoid plate | 47 (20.1%) | 0 (0.0%) | <0.001 |
| Jugular foramen | 36 (15.0%) | 2 (2.1%) | <0.001 |
| Nasal cavity | 21 (9.0%) | 0 (0.0%) | 0.171 |
| Parotid gland | 21 (9.0%) | 0 (0.0%) | 0.001 |
| Lateral pterygoid muscle | 19 (8.1%) | 0 (0.0%) | 0.001 |

| Prevertebral muscle | Invasion (n = 182) | Non-invasion (n = 149) |
|---------------------|-------------------|----------------------|
| Meninges | 82 (45.1%) | 9 (6.0%) | <0.001 |
| Pterygopalatine fossa | 59 (32.4%) | 21 (14.1%) | <0.001 |
| Poststyloid compartment | 78 (42.9%) | 2 (1.3%) | <0.001 |
| Cavernous sinus | 68 (37.4%) | 7 (4.7%) | <0.001 |
| Medial pterygoid muscle | 56 (30.8%) | 13 (8.7%) | <0.001 |
| Oropharynx | 51 (28.0%) | 7 (4.7%) | <0.001 |
| Hypoglossal canal | 54 (29.7%) | 0 (0.0%) | <0.001 |
| Foramen rotundum | 44 (24.2%) | 8 (5.4%) | <0.001 |
| Lateral pterygoid plate | 37 (20.3%) | 10 (6.7%) | <0.001 |
| Jugular foramen | 36 (19.8%) | 1 (0.7%) | <0.001 |
| Nasal cavity | 13 (7.1%) | 12 (8.1%) | 0.755 |
| Parotid gland | 21 (11.5%) | 0 (0.0%) | <0.001 |
| Lateral pterygoid muscle | 15 (8.2%) | 4 (2.7%) | 0.034 |

| Foramen lacerum | Invasion (n = 176) | Non-invasion (n = 155) |
|----------------|-------------------|----------------------|
| Meninges | 90 (51.1%) | 1 (0.6%) | <0.001 |
| Pterygopalatine fossa | 69 (39.2%) | 11 (7.1%) | <0.001 |
| Poststyloid compartment | 71 (40.3%) | 9 (5.8%) | <0.001 |
| Cavernous sinus | 74 (42.0%) | 1 (0.6%) | <0.001 |
| Medial pterygoid muscle | 64 (36.4%) | 5 (3.2%) | <0.001 |
| Oropharynx | 49 (27.8%) | 9 (5.8%) | <0.001 |
| Hypoglossal canal | 54 (30.7%) | 0 (0.0%) | <0.001 |
| Foramen rotundum | 49 (27.8%) | 3 (1.9%) | <0.001 |
| Lateral pterygoid plate | 44 (25.0%) | 3 (1.9%) | <0.001 |
| Jugular foramen | 37 (21.0%) | 0 (0.0%) | <0.001 |
| Nasal cavity | 19 (10.8%) | 6 (3.9%) | 0.017 |
| Parotid gland | 21 (11.9%) | 0 (0.0%) | <0.001 |
| Lateral pterygoid muscle | 19 (10.8%) | 0 (0.0%) | <0.001 |

(Continued)
TABLE 3 | Continued

| Medium-risk regions | Tumor invasion | $p$ |
|---------------------|----------------|-----|
|                     | Invasion ($n = 160$) | Non-invasion ($n = 171$) |
| **Medial pterygoid plate** | | |
| Meninges | 75 (46.9%) | 16 (9.4%) | <0.001 |
| Pterygopalatine fossa | 78 (48.8%) | 2 (1.2%) | <0.001 |
| Poststyloid compartment | 57 (35.6%) | 23 (13.5%) | <0.001 |
| Cavernous sinus | 61 (38.1%) | 14 (8.2%) | <0.001 |
| Medial pterygoid muscle | 67 (41.9%) | 2 (1.2%) | <0.001 |
| Pterygopalatine fossa | 42 (26.3%) | 16 (9.4%) | <0.001 |
| Poststyloid compartment | 41 (25.6%) | 13 (7.6%) | <0.001 |
| Cavernous sinus | 48 (30.0%) | 4 (2.3%) | <0.001 |
| Medial pterygoid muscle | 47 (29.4%) | 0 (0.0%) | <0.001 |
| Jugular foramen | 29 (18.1%) | 8 (4.7%) | <0.001 |
| Nasal cavity | 24 (15.0%) | 1 (0.6%) | <0.001 |
| Parotid gland | 19 (11.9%) | 2 (1.2%) | <0.001 |
| Lateral pterygoid muscle | 19 (11.9%) | 0 (0.0%) | <0.001 |
| **Sphenoidal sinus** | | |
| Meninges | 91 (59.5%) | 0 (0.0%) | <0.001 |
| Pterygopalatine fossa | 69 (45.1%) | 11 (6.2%) | <0.001 |
| Poststyloid compartment | 59 (38.6%) | 21 (11.8%) | <0.001 |
| Cavernous sinus | 75 (49.0%) | 0 (0.0%) | <0.001 |
| Medial pterygoid muscle | 61 (39.9%) | 8 (4.5%) | <0.001 |
| Oropharynx | 39 (25.5%) | 19 (10.7%) | <0.001 |
| Hypoglossal canal | 51 (33.3%) | 3 (1.7%) | <0.001 |
| Foramen rotundum | 52 (34.0%) | 0 (0.0%) | <0.001 |
| Lateral pterygoid plate | 45 (29.4%) | 2 (1.1%) | <0.001 |
| Jugular foramen | 34 (22.2%) | 3 (1.7%) | <0.001 |
| Nasal cavity | 21 (13.7%) | 4 (2.2%) | <0.001 |
| Parotid gland | 20 (13.1%) | 1 (0.6%) | <0.001 |
| Lateral pterygoid muscle | 19 (12.4%) | 0 (0.0%) | <0.001 |
| **Clivus** | | |
| Meninges | 83 (55.3%) | 8 (4.4%) | <0.001 |
| Pterygopalatine fossa | 59 (39.3%) | 21 (11.6%) | <0.001 |
| Poststyloid compartment | 64 (42.7%) | 16 (8.8%) | <0.001 |
| Cavernous sinus | 69 (46.0%) | 6 (3.3%) | <0.001 |
| Medial pterygoid muscle | 58 (38.7%) | 11 (6.1%) | <0.001 |
| Oropharynx | 43 (28.7%) | 15 (8.3%) | <0.001 |
| Hypoglossal canal | 53 (35.3%) | 1 (0.6%) | <0.001 |
| Foramen rotundum | 43 (28.7%) | 9 (5.0%) | <0.001 |
| Lateral pterygoid plate | 40 (26.7%) | 7 (3.9%) | <0.001 |
| Jugular foramen | 36 (24.0%) | 1 (0.6%) | <0.001 |
| Nasal cavity | 15 (10.0%) | 10 (5.5%) | 0.125 |
| Parotid gland | 20 (13.3%) | 1 (0.6%) | <0.001 |
| Lateral pterygoid muscle | 15 (10.0%) | 4 (2.2%) | 0.003 |
| **Petrosal apex** | | |
| Meninges | 85 (63.0%) | 6 (3.1%) | <0.001 |
| Pterygopalatine fossa | 56 (41.5%) | 24 (12.2%) | <0.001 |
| Poststyloid compartment | 68 (50.4%) | 12 (6.1%) | <0.001 |
| Cavernous sinus | 70 (51.9%) | 5 (2.6%) | <0.001 |
| Medial pterygoid muscle | 58 (43.0%) | 11 (5.6%) | <0.001 |
| Oropharynx | 46 (34.1%) | 12 (6.1%) | <0.001 |
| Hypoglossal canal | 54 (40.0%) | 0 (0.0%) | <0.001 |
| Foramen rotundum | 43 (31.9%) | 9 (4.8%) | <0.001 |
| Lateral pterygoid plate | 40 (29.6%) | 7 (3.6%) | <0.001 |
| Jugular foramen | 37 (27.4%) | 0 (0.0%) | <0.001 |
| Nasal cavity | 12 (8.9%) | 13 (6.6%) | 0.445 |
| Parotid gland | 21 (15.6%) | 0 (0.0%) | <0.001 |
| Lateral pterygoid muscle | 17 (12.6%) | 2 (1.0%) | <0.001 |

(Continued)
One patient showed a medial group of retropharyngeal lymph node metastasis. No lymph node metastasis was observed in levels Ia, VI, IX, or Xb (Table 6).

In the 311 patients with lymph node metastasis, the involvement rates of the upper neck (levels IIa, IIb, VIIa, and VIIb), middle neck (levels III and Va), and lower neck (levels IVa, IVb, Vb, and Vc) were 100.0% (311/311), 49.5% (154/311), and 11.6% (36/311), respectively, and skip metastasis occurred in only 1.9% (6/311) of patients (Figure 2). In the 64 patients who had unilateral upper neck involvement, the involvement rates of ipsilateral levels III, Va, IVa, IVb, Vb, and Vc were 26.6% (17/64), 12.5% (8/64), 3.1% (2/64), 1.6% (1/64), 3.1% (2/64), and 0.0% (0/64), respectively, whereas the involvement rate of contralateral level III was only 1.6% (1/64) and no lymph node metastasis was observed in contralateral levels Va, IVa, IVb, Vb, and Vc. For patients with bilateral upper neck involvement, the involvement rates of levels III, Va, IVa, IVb, Vb, and Vc were 50.2% (124/247), 15.4% (38/247), 10.9% (27/247), 4.5% (11/247), 2.4% (6/247), and 1.2% (3/247), respectively.

**DISCUSSION**

The emergence of PET/MR has not only brought about higher accuracy for staging patients with NPCs, but it has also reduced radiation dose and wait time for different scans (5). However, the role of PET/MR for the target volume delineation of NPC is limited. This study has shown the locoregional extension patterns based on PET/MRI in NPCs by concrete evidence to improve CTV delineation.

### Table 3 | Incidence rates of skull-base invasion for nasopharyngeal carcinoma.

| Anatomic sites                  | No. of patients (%) |
|---------------------------------|---------------------|
| Prevertebral muscle             | 54 (16.3)           |
| Foramen lacerum                 | 32 (9.7)            |
| Prestyloid compartment          | 28 (8.5)            |
| Petrous apex                    | 14 (4.2)            |
| Medial pterygoid plate          | 12 (3.6)            |
| Foramen ovale                   | 7 (2.1)             |
| Hypoglossal canal               | 6 (1.8)             |
| Petrygopalatine fossa           | 5 (1.5)             |
| Foramen rotundum                | 3 (0.9)             |
| Medial pterygoid muscle         | 3 (0.9)             |
| Poststyloid compartment         | 3 (0.9)             |
| Oropharynx                      | 3 (0.9)             |
| Nasal cavity                    | 2 (0.6)             |
| Jugular foramen                 | 2 (0.6)             |
| Orbit                           | 1 (0.3)             |
| Maxillary sinus                 | 0 (0)               |
| Lateral pterygoid plate         | 0 (0)               |
| Lateral pterygoid muscle        | 0 (0)               |

*(Figure 1)*. One patient showed a medial group of retropharyngeal lymph node metastasis. No lymph node metastasis was observed in levels Ia, VI, IX, or Xb (Table 6).

In the 311 patients with lymph node metastasis, the involvement rates of the upper neck (levels IIa, IIb, VIIa, and VIIb), middle neck (levels III and Va), and lower neck (levels IVa, IVb, Vb, and Vc) were 100.0% (311/311), 49.5% (154/311), and 11.6% (36/311), respectively, and skip metastasis occurred in only 1.9% (6/311) of patients (Figure 2). In the 64 patients who had unilateral upper neck involvement, the involvement rates of ipsilateral levels III, Va, IVa, IVb, Vb, and Vc were 26.6% (17/64), 12.5% (8/64), 3.1% (2/64), 1.6% (1/64), 3.1% (2/64), and 0.0% (0/64), respectively, whereas the involvement rate of contralateral level III was only 1.6% (1/64) and no lymph node metastasis was observed in contralateral levels Va, IVa, IVb, Vb, and Vc. For patients with bilateral upper neck involvement, the involvement rates of levels III, Va, IVa, IVb, Vb, and Vc were 50.2% (124/247), 15.4% (38/247), 10.9% (27/247), 4.5% (11/247), 2.4% (6/247), and 1.2% (3/247), respectively.

**DISCUSSION**

The emergence of PET/MR has not only brought about higher accuracy for staging patients with NPCs, but it has also reduced radiation dose and wait time for different scans (5). However, the role of PET/MR for the target volume delineation of NPC is limited. This study has shown the locoregional extension patterns based on PET/MRI in NPCs by concrete evidence to improve CTV delineation.
For the local extension pattern, the risk of tumor invasion into various anatomic sites surrounding the nasopharynx was closely associated with the distance to the nasopharynx. The regions at high risk, such as the basis of the sphenoid bone, prestyloid compartment, and prevertebral muscle were adjacent to the nasopharynx, whereas the regions at medium or low risk (except nasal cavity and oropharynx) were distant from the nasopharynx. When the high-risk regions were involved, the rates of tumor invasion into the medium-risk regions increased especially for the adjacent medium-risk regions. Our data indicate that the primary disease spreads stepwise from proximal regions to distal regions and primary disease skipping is unusual, which is similar to the findings of head and neck MRI (11, 14).

King et al. reported 246 patients suspected of having NPC who underwent MRI, endoscopy, and endoscopic biopsy. The sensitivity, specificity, and accuracy of MRI were 100%, 93%, and 95%, respectively (15). In the present study, 94.0% of patients had bilateral tumor invasion in the nasopharynx. However, the regions including the skull base foramina are at low risk of concurrent bilateral tumor invasion (<10%) with the exception of the prevertebral muscle. In the study including 205 NPC patients with intracranial extension, the incidence rates of concurrent bilateral tumor invasion into the foramen lacerum, foramen ovale, and foramen rotundum were 47.8%, 8.8%, and 6.8%, respectively (16). The CTV including the whole nasopharynx and bilateral foramina ovale, foramina rotunda, and foramina lacerar irrespective of T classification should be reevaluated (4).

For the pattern of regional lymph node metastasis, the rates of lymph node metastasis from the upper neck to the lower neck decreased successively, and skip metastasis happened only in 1.9% of patients, which further confirms the MRI findings from Li et al. (14). In the Li et al.’s study using head and neck MRI (14), the rates of lymph node metastasis of the middle and lower neck for patients with cervical lymph node metastasis were 30.2% and 7.2%, respectively, which were lower than the present study using PET/MRI. In the study including 113 patients with histologically confirmed NPC, the sensitivity of PET/MRI

---

**TABLE 6** | Incidence rates of nodal spread for nasopharyngeal carcinoma.

| Level  | Bilateral | Left   | Right  |
|--------|-----------|--------|--------|
| Level VIIa* | 98 (29.6) | 62 (18.7) | 76 (23.0) |
| Level VIIb | 0 (0)     | 5 (1.5)  | 3 (0.9)  |
| Level IIa | 149 (45.0) | 52 (15.7) | 55 (16.6) |
| Level IIb | 147 (44.4) | 51 (15.4) | 53 (16.0) |
| Level III | 32 (9.7)   | 59 (17.6) | 50 (15.1) |
| Level IVa | 14 (4.2)   | 23 (6.9)  | 21 (6.3)  |
| Level IVb | 0 (0)     | 8 (2.4)   | 3 (0.9)   |
| Level Va  | 1 (0.3)   | 14 (4.2)  | 13 (3.9)  |
| Level Vb  | 0 (0)     | 6 (1.8)   | 2 (0.6)   |
| Level Vc  | 0 (0)     | 2 (0.6)   | 1 (0.3)   |
| Level Ib  | 2 (0.6)   | 7 (2.1)   | 3 (0.9)   |
| Level IIb | 0 (0)     | 5 (1.5)   | 1 (0.3)   |
| Level VIII | 0 (0)    | 1 (0.3)   | 0 (0)     |
| Level Xa  | 0 (0)     | 0 (0)     | 0 (0)     |

*Medial group of retropharyngeal lymph node metastasis in 1 patient.
FIGURE 2 | The pattern of lymph node metastasis.

FIGURE 3 | Involved level radiotherapy for nasopharyngeal carcinoma.
(99.5%) was higher than that of head and neck MRI (94.2%) in terms of the N staging assessment (5).

According to the 2013 updated consensus guidelines of the neck node levels, the involvement rates of levels IVb, Vb, Vc, and VIIb were not higher than level Ib (3.6%). In the present international guideline for the delineation of the CTV for NPC, level Ib was not included in the CTV, except the special cases, such as involvement of the submandibular gland (4). For patients who had unilateral upper neck involvement, the involvement rates of ipsilateral levels III, Va, IVa, IVb, Vb, and Vc were 26.6%, 12.5%, 3.1%, 1.6%, 3.1%, and 0.0%, respectively, whereas the involvement rate of contralateral level III was only 1.6% and no lymph node metastasis was observed in contralateral levels Va, IVa, IVb, Vb, and Vc. It might be unreasonable to cover cervical lymph node levels IVa, IVb, Vb, and Vc ipsilaterally for CTV if there are any involved lymph nodes in the ipsilateral neck (excluding retropharyngeal lymph nodes) (4, 17). With the development of imaging and treatment, radiotherapy for Hodgkin lymphoma has changed from the very large extended-field radiotherapy to the very limited involved-site radiotherapy (18). For NPC in the era of PET/MR, involved level radiotherapy might be feasible for cervical lymph node levels below the caudal border of the cricoid cartilage and level VIIb (Figure 3).

In 2020, Zhang et al. reported the current CTV delineation for the primary site of T3 classification NPC among five large tertiary cancer centers in China. Two different CTV designs were used and the variances in the coverage of some regions including cavernous sinus, posterior space of styloid process, and posterior pharyngeal wall were significant among physicians (19). Guo et al. reported 471 patients with non-metastatic NPCs treated by de-intensification technique omitting the CTV1 and narrowing the margin of CTV2 from 10 mm to 8 mm. The 4-year local recurrence-free survival and overall survival rates were 96.6% and 92.4%, respectively (2). Most commonly, the GTV is homogeneously covered during radiotherapy planning. However, tumors are known to be very heterogeneous. The use of PET/CT to construct a tumor voxel dose-response matrix and dose prescription function for adaptive dose painting by number has been investigated in head and neck cancer (20). With the development of artificial intelligence, automated delineation and segmentation methods have been adopted for NPC and PET/MR radiomics-based dose painting should be evaluated in the near future (21, 22).

CONCLUSION

For NPCs, primary disease and regional lymph node spread follow an orderly pattern and a skip pattern of lymph node metastasis was unusual. Involved level radiotherapy might be feasible for cervical lymph node levels below the caudal border of the cricoid cartilage and level VIIb.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Hospital Ethics Committee at Zhejiang Cancer Hospital. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

Study conception and design: CC and XC. Data acquisition: CC, YX, SH, FJ, TJ, QJ, YH, QH, and XC. Data analysis and interpretation: YX, SH, FJ, TJ, QJ, YH, and QH. Quality control of data and algorithms: CC, YX, SH, FJ, TJ, QJ, YH, QH, and XC. Manuscript writing: CC and XC. Manuscript reviewing and approving: CC and XC. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by a grant from the Natural Science Foundation of Zhejiang Province (Nos. LGF19H160007 and LGF20H160007).

REFERENCES

1. Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal Carcinoma. Lancet (2019) 394(10192):64–80. doi: 10.1016/S0140-6736(19)30956-0
2. Guo Q, Zheng Y, Lin J, Xu Y, Hu C, Zong J, et al. Modified Reduced-Volume Intensity-Modulated Radiation Therapy in non-Metastatic Nasopharyngeal Carcinoma: A Prospective Observation Series. Radiother Oncol (2021) 156:251–7. doi: 10.1016/j.radonc.2020.12.035
3. NCCN Guidelines Version 1 (2021). Available at: http://www.nccn.org/ (Accessed 24 April 2021).
4. Lee AW, Ng WT, Pan JJ, Poh SS, Ahn YC, AlHussain H, et al. International Guideline for the Delineation of the Clinical Target Volumes (CTV) for Nasopharyngeal Carcinoma. Radiother Oncol (2018) 126(1):25–36. doi: 10.1016/j.radonc.2017.10.032
5. Chan SC, Yeh CH, Yen TC, Ng SH, Chang JT, Lin CY, et al. Clinical Utility of Simultaneous Whole-Body 18 F-FDG PET/MRI as a Single-Step Imaging Modality in the Staging of Primary Nasopharyngeal Carcinoma. Eur J Nucl Med Mol Imaging (2018) 45(8):1297–308. doi: 10.1007/s00259-018-3986-3
6. Cao C, Yang P, Xu Y, Niu T, Hu Q, Chen X. Feasibility of Multiparametric Imaging With PET/MR in Nasopharyngeal Carcinoma: A Pilot Study. Oral Oncol (2019) 93:91–5. doi: 10.1016/j.oraloncology.2019.04.021
7. Piao Y, Cao C, Xu Y, Huang S, Jiang F, Jin T, et al. Detection and Staging of Recurrent or Metastatic Nasopharyngeal Carcinoma in the Era of FDG PET/ MR. Eur Arch Otorhinolaryngol (2021). doi: 10.1007/s00405-021-06779-5
8. Brierley J, Gospodarowicz M, Wittekind C. UICC TNM Classification of Malignant Tumours. Eighth ed. Chichester: Wiley (2017).
9. Amin MB, Edge S, Greene F, Schilsky R, Washington M, et al. AJCC Cancer Staging Manual. Eighth ed. New York: Springer (2017).
10. Cao C, Jiang F, Jin Q, Jin T, Huang S, Hu Q, et al. Paranasal Sinus Invasion in Nasopharyngeal Carcinoma After Intensity-Modulated Radiotherapy. Cancer Res Treat (2019) 51(1):73–9. doi: 10.4143/crt.2017.607
11. Liang SB, Sun Y, Liu LZ, Chen Y, Chen L, Mao YP, et al. Extension of Local Disease in Nasopharyngeal Carcinoma Detected by Magnetic Resonance Imaging: Improvement of Clinical Target Volume Delineation. Int J Radiat Oncol Biol Phys (2009) 73(3):742–50. doi: 10.1016/j.ijrobp.2008.11.053
12. Cao C, Luo J, Gao L, Yi J, Huang X, Li S, et al. Magnetic Resonance Imaging-Detected Intracranial Extension in the T4 Classification Nasopharyngeal Carcinoma With Intensity-Modulated Radiotherapy. Cancer Res Treat (2017) 49(2):518–25. doi: 10.4143/crt.2016.299
13. Grégoire V, Ang K, Budach W, Grau C, Hamoir M, Langendijk JA, et al. Delineation of the Neck Node Levels for Head and Neck Tumors: A 2013 Update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG Consensus Guidelines. Radiother Oncol (2014) 110(1):172–81. doi: 10.1016/j.radonc.2013.10.010
14. Li WF, Sun Y, Chen M, Tang LL, Liu LZ, Mao YP, et al. Locoregional Extension Patterns of Nasopharyngeal Carcinoma and Suggestions for Clinical Target Volume Delineation. Chin J Cancer (2012) 31(12):579–87. doi: 10.5372/jcc.012.10095
15. King AD, Vlantis AC, Bhatia KS, Woo JK, Tse GM, et al. Primary Nasopharyngeal Carcinoma: Diagnostic Accuracy of MR Imaging Versus That of Endoscopy and Endoscopic Biopsy. Radiology (2011) 258(2):531–7. doi: 10.1148/radiol.10101241
16. Cao C, Jiang F, Jin Q, Jin T, Huang S, Hu Q, et al. Locoregional Extension and Patterns of Failure for Nasopharyngeal Carcinoma With Intracranial Extension. Oral Oncol (2018) 79:27–32. doi: 10.1016/j.oraloncology.2018.02.004
17. Biau J, Lapeyre M, Troussier I, Budach W, Giralt J, Grau C, et al. Selection of Lymph Node Target Volumes for Definitive Head and Neck Radiation Therapy: A 2019 Update. Radiother Oncol (2019) 134:1–9. doi: 10.1016/j.radonc.2019.01.018
18. Momotow J, Borzhmann S, Eichenauer DA, Engert A, Sasse S. Hodgkin Lymphoma—Review on Pathogenesis, Diagnosis, Current and Future Treatment Approaches for Adult Patients. J Clin Med (2021) 10(5):1125. doi: 10.3390/jcm10051125
19. Zhang S, Yang S, Xu P, Xu Y, Zhou G, Ou X, et al. Variations of Clinical Target Volume Delineation for Primary Site of Nasopharyngeal Cancer Among Five Centers in China. Front Oncol (2020) 10:1572. doi: 10.3389/fonc.2020.01572
20. Yan D, Chen S, Krauss DJ, Chen PY, Chinnaiyan P, Wilson GD. Tumor Voxel Dose-Response Matrix and Dose Prescription Function Derived Using 18F-FDG PET/CT Images for Adaptive Dose Painting by Number. Int J Radiat Oncol Biol Phys (2019) 104(1):207–18. doi: 10.1016/j.ijrobp.2019.01.077
21. Lin L, Dou Q, Jin YM, Zhou GQ, Tang YQ, Chen WL, et al. Deep Learning for Automated Contouring of Primary Tumor Volumes by MRI for Nasopharyngeal Carcinoma. Radiology (2019) 291(3):677–86. doi: 10.1148/radiol.2019182012
22. Schick U, Lucia F, Bourbonne V, Dissaux G, Pradier O, Jaouen V, et al. Use of Radiomics in the Radiation Oncology Setting: Where do We Stand and What do We Need? Cancer Radiother (2020) 24(6-7):755–61. doi: 10.1016/j.canrad.2020.07.005

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Cao, Xu, Huang, Jiang, Jin, Jin, Hua, Hu and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.